Apalutamide (ARN-509) 在非转移性去势抵抗性前列腺癌患者中的研究 (SPARTAN)
ARN-509 在非转移性 (M0) 去势抵抗性前列腺癌患者中的多中心、随机、双盲、安慰剂对照的 III 期研究
The purpose of this study is to evaluate the efficacy and safety of apalutamide in adult men with high-risk non-metastatic castration-resistant prostate cancer.
研究概览
详细说明
This Phase 3 clinical trial is an essential step in the evaluation of an investigational medication to see if it may be useful in treating prostate cancer. The purpose of the SPARTAN study is to compare the safety and effectiveness of the investigational medication to placebo in delaying prostate cancer from spreading to other parts of the body. A placebo is a pill that looks like the investigational medication but does not contain any active medication, a dummy pill.
Phase 3 studies are performed after preliminary evidence suggesting effectiveness of the drug has been obtained in previous Phase 2 studies. These studies are intended to gather the additional information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the drug.
Study participants will take the oral investigational medication daily. One cycle of study treatment lasts 4 weeks or 28 days. The number of cycles will depend on how you and your cancer respond to the study medication.
In order for the researchers to evaluate and compare the study results, there are two different study groups. Study participants will be randomly (like flipping a coin) assigned to one of these groups:
- One group will receive their current treatment along with the investigational medication
- One group will receive their current medications along with a placebo
The investigational medication will be given to 2 out of every 3 study participants. Neither you nor the study staff will know which group you are in. However, in case of a medical emergency, your study doctor can quickly find out which treatment group you are in.
All participants will continue to receive their current treatment along with either the investigational medication or a placebo. The selections will be random, and you may remain on investigational treatment until your disease worsens, or until significant side effects occur or you can no longer tolerate treatment.
研究类型
注册 (实际的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
-
Aalborg C、丹麦
-
Copenhagen、丹麦
-
Odense、丹麦
-
Roskilde、丹麦
-
-
-
-
-
Haifa、以色列
-
Jeruselem、以色列
-
Kfar Saba、以色列
-
Petah Tikva、以色列
-
Ramat Gan、以色列
-
Tel Aviv、以色列
-
Tsrifin、以色列
-
-
-
-
-
Barnaul、俄罗斯
-
Ivanovo、俄罗斯
-
Moscow、俄罗斯
-
Obninsk、俄罗斯
-
Omsk、俄罗斯
-
Ryazan、俄罗斯
-
Saint Petersburg、俄罗斯
-
Ufa、俄罗斯
-
Yaroslavl、俄罗斯
-
Yekaterinburg、俄罗斯
-
-
-
-
Alberta
-
Calgary、Alberta、加拿大
-
Edmonton、Alberta、加拿大
-
-
British Columbia
-
Abbotsford British Columbia、British Columbia、加拿大
-
Kelowna、British Columbia、加拿大
-
Vancouver、British Columbia、加拿大
-
Victoria、British Columbia、加拿大
-
-
New Brunswick
-
Moncton、New Brunswick、加拿大
-
Saint John、New Brunswick、加拿大
-
-
Nova Scotia
-
Halifax、Nova Scotia、加拿大
-
-
Ontario
-
Barrie、Ontario、加拿大
-
Brampton、Ontario、加拿大
-
Brantford、Ontario、加拿大
-
Hamilton、Ontario、加拿大
-
London、Ontario、加拿大
-
North York、Ontario、加拿大
-
Oakville、Ontario、加拿大
-
Ottawa、Ontario、加拿大
-
Owen Sound、Ontario、加拿大
-
Toronto、Ontario、加拿大
-
-
Quebec
-
Gatineau、Quebec、加拿大
-
Granby、Quebec、加拿大
-
Greenfield Park、Quebec、加拿大
-
Laval、Quebec、加拿大
-
Montreal、Quebec、加拿大
-
Pointe-Claire、Quebec、加拿大
-
Québec、Quebec、加拿大
-
Sherbrooke、Quebec、加拿大
-
-
-
-
-
Budapest、匈牙利
-
Miskolc、匈牙利
-
Nyíregyhá、匈牙利
-
Sopron、匈牙利
-
Szentes、匈牙利
-
-
-
-
-
Kaohsiung City、台湾
-
Taichung、台湾
-
Taipei、台湾
-
Taoyuan County、台湾
-
-
-
-
-
Graz、奥地利
-
Innsbruck、奥地利
-
Linz、奥地利
-
Vienna、奥地利
-
-
-
-
-
Aachen、德国
-
Bergisch Gladbach、德国
-
Berlin、德国
-
Braunschweig、德国
-
Cologne、德国
-
Duisburg、德国
-
Emmendingen、德国
-
Frankfurt am Main、德国
-
Greifswald、德国
-
Göttingen、德国
-
Hamburg、德国
-
Hanover、德国
-
Heidelberg、德国
-
Heinsberg、德国
-
Homburg/Saar、德国
-
Jena、德国
-
Kiel、德国
-
Kirchheim unter Teck、德国
-
Magdeburg、德国
-
Mainz、德国
-
Mannheim、德国
-
Marburg、德国
-
Mettmann、德国
-
Müllheim、德国
-
Münster、德国
-
Nürtingen、德国
-
Regensburg、德国
-
Rostock、德国
-
Tübingen、德国
-
Weiden、德国
-
Wilhelmshaven、德国
-
Wuppertan、德国
-
Zirndorf、德国
-
-
-
-
-
Nordbyhagen、挪威
-
-
-
-
-
Liberec、捷克语
-
Olomouc、捷克语
-
Opava、捷克语
-
Pilsen、捷克语
-
Prague、捷克语
-
-
-
-
-
Banská Bystrica、斯洛伐克
-
Bratislava、斯洛伐克
-
Martin、斯洛伐克
-
Nitra、斯洛伐克
-
Trenčín、斯洛伐克
-
-
-
-
-
Auckland、新西兰
-
Christchurch、新西兰
-
Hamilton、新西兰
-
Nelson、新西兰
-
Tauranga、新西兰
-
Whangarei、新西兰
-
-
-
-
-
Akita、日本
-
Fukuoka、日本
-
Gifu、日本
-
Hakodate、日本
-
Hiroshima、日本
-
Hokkaido、日本
-
Kanazawa、日本
-
Kashiwa、日本
-
Kita-Gun、日本
-
Kobe、日本
-
Koshigaya、日本
-
Kumamoto、日本
-
Kurume、日本
-
Matsuyama、日本
-
Nagano、日本
-
Nagasaki、日本
-
Nagoya、日本
-
Niigata、日本
-
Osaka、日本
-
Sagamihara、日本
-
Sakura、日本
-
Sapporo、日本
-
Shinjuku-Ku、日本
-
Tokushima、日本
-
Tokyo、日本
-
Ube、日本
-
Wakayama、日本
-
Yokohama、日本
-
Ōsaka-sayama、日本
-
-
-
-
-
Brussels、比利时
-
Ghent、比利时
-
Kortrijk、比利时
-
Leuven、比利时
-
Liège、比利时
-
Ottignies、比利时
-
-
-
-
-
Angers、法国
-
Besançon、法国
-
Bordeaux、法国
-
Caen Cédex 05、法国
-
Clermont-Ferrand、法国
-
Hyers、法国
-
La Roche-sur-Yon、法国
-
Le Mans、法国
-
Lille Cedex N/a、法国
-
Lyon、法国
-
Marseille、法国
-
Nice、法国
-
Nîmes、法国
-
Paris、法国
-
Reims、法国
-
Rennes、法国
-
Rouen、法国
-
Saint-Grégoire、法国
-
Saint-Herblain、法国
-
Strasbourg、法国
-
Suresnes、法国
-
Tours、法国
-
Vandœuvre-lès-Nancy、法国
-
-
-
-
-
Bialystok、波兰
-
Bydgoszcz、波兰
-
Gdansk、波兰
-
Kutno、波兰
-
Lodz、波兰
-
Poznan、波兰
-
Szczecin、波兰
-
Torun、波兰
-
Warsaw、波兰
-
Wroclaw、波兰
-
-
-
-
-
Adelaide、澳大利亚
-
Box Hill、澳大利亚
-
Camperdown、澳大利亚
-
Darlinghurst、澳大利亚
-
Geelong、澳大利亚
-
Gosford、澳大利亚
-
Hobart、澳大利亚
-
Kogarah、澳大利亚
-
Liverpool、澳大利亚
-
Melbourne、澳大利亚
-
Nedlands、澳大利亚
-
Parkville、澳大利亚
-
South Woodville、澳大利亚
-
Southport、澳大利亚
-
Sydney、澳大利亚
-
Tweed Heads、澳大利亚
-
Wollongong、澳大利亚
-
-
-
-
-
Gothenburg、瑞典
-
Stockholm、瑞典
-
Umeå、瑞典
-
Uppsala、瑞典
-
Örebro、瑞典
-
-
-
-
-
Baia Mare、罗马尼亚
-
Brasov、罗马尼亚
-
Bucharest、罗马尼亚
-
Cluj-Napoca、罗马尼亚
-
Târgu Mureş、罗马尼亚
-
-
-
-
Alabama
-
Birmingham、Alabama、美国
-
-
Alaska
-
Anchorage、Alaska、美国
-
-
Arizona
-
Chandler、Arizona、美国
-
Tucson、Arizona、美国
-
-
California
-
Duarte、California、美国
-
Fullerton、California、美国
-
Laguna Woods、California、美国
-
Los Angeles、California、美国
-
Orange、California、美国
-
Roseville、California、美国
-
Sacramento、California、美国
-
San Bernardino、California、美国
-
San Diego、California、美国
-
San Francisco、California、美国
-
Santa Monica、California、美国
-
Sherman Oaks、California、美国
-
Stanford、California、美国
-
Tarzana、California、美国
-
Torrance、California、美国
-
-
Colorado
-
Denver、Colorado、美国
-
Englewood、Colorado、美国
-
Glenwood Springs、Colorado、美国
-
Grand Junction、Colorado、美国
-
-
District of Columbia
-
Washington D.C.、District of Columbia、美国
-
-
Florida
-
Aventura、Florida、美国
-
Boca Raton、Florida、美国
-
Bradenton、Florida、美国
-
Daytona Beach、Florida、美国
-
Fort Myers、Florida、美国
-
Hialeah、Florida、美国
-
Jacksonville、Florida、美国
-
Miami、Florida、美国
-
New Port Richey、Florida、美国
-
Orlando、Florida、美国
-
Sarasota、Florida、美国
-
St. Petersburg、Florida、美国
-
Wellington、Florida、美国
-
-
Idaho
-
Meridian、Idaho、美国
-
-
Illinois
-
Chicago、Illinois、美国
-
Decatur、Illinois、美国
-
Maywood、Illinois、美国
-
Melrose Park、Illinois、美国
-
-
Indiana
-
Carmel、Indiana、美国
-
Jeffersonville、Indiana、美国
-
Muncie、Indiana、美国
-
-
Iowa
-
West Des Moines、Iowa、美国
-
-
Kansas
-
Westwood、Kansas、美国
-
Wichita、Kansas、美国
-
-
Louisiana
-
Metairie、Louisiana、美国
-
New Orleans、Louisiana、美国
-
-
Maryland
-
Annapolis、Maryland、美国
-
Baltimore、Maryland、美国
-
Rockville、Maryland、美国
-
Towson、Maryland、美国
-
-
Massachusetts
-
Boston、Massachusetts、美国
-
-
Michigan
-
Detroit、Michigan、美国
-
Lansing、Michigan、美国
-
Minneapolis、Michigan、美国
-
Royal Oak、Michigan、美国
-
-
Minnesota
-
Duluth、Minnesota、美国
-
-
Mississippi
-
Bay Saint Louis、Mississippi、美国
-
Southaven、Mississippi、美国
-
-
Missouri
-
Kansas City、Missouri、美国
-
-
Montana
-
Missoula、Montana、美国
-
-
Nebraska
-
Omaha、Nebraska、美国
-
-
Nevada
-
Las Vegas、Nevada、美国
-
-
New Hampshire
-
Hooksett、New Hampshire、美国
-
-
New Jersey
-
Hackensack、New Jersey、美国
-
Lawrenceville、New Jersey、美国
-
Morristown、New Jersey、美国
-
Mount Laurel、New Jersey、美国
-
New Brunswick、New Jersey、美国
-
Voorhees Township、New Jersey、美国
-
-
New Mexico
-
Albuquerque、New Mexico、美国
-
-
New York
-
Albany、New York、美国
-
Mineola、New York、美国
-
New York、New York、美国
-
Oneida、New York、美国
-
Poughkeepsie、New York、美国
-
Syracuse、New York、美国
-
The Bronx、New York、美国
-
-
North Carolina
-
Concord、North Carolina、美国
-
Greensboro、North Carolina、美国
-
Greenville、North Carolina、美国
-
Salisbury、North Carolina、美国
-
Winston-Salem、North Carolina、美国
-
-
Ohio
-
Cincinnati、Ohio、美国
-
Cleveland、Ohio、美国
-
Middleburg Heights、Ohio、美国
-
Middletown、Ohio、美国
-
-
Oregon
-
Bend、Oregon、美国
-
Portland、Oregon、美国
-
Tualatin、Oregon、美国
-
-
Pennsylvania
-
Bala-Cynwyd、Pennsylvania、美国
-
Bryn Mawr、Pennsylvania、美国
-
Lancaster、Pennsylvania、美国
-
Philadelphia、Pennsylvania、美国
-
Pittsburgh、Pennsylvania、美国
-
-
Rhode Island
-
Warwick、Rhode Island、美国
-
-
South Carolina
-
Charleston、South Carolina、美国
-
Greenville、South Carolina、美国
-
Myrtle Beach、South Carolina、美国
-
West Columbia、South Carolina、美国
-
-
Tennessee
-
Memphis、Tennessee、美国
-
Nashville、Tennessee、美国
-
-
Texas
-
Abilene、Texas、美国
-
Amarillo、Texas、美国
-
Dallas、Texas、美国
-
Fort Sam Houston、Texas、美国
-
Houston、Texas、美国
-
McAllen、Texas、美国
-
San Antonio、Texas、美国
-
-
Virginia
-
Norfolk、Virginia、美国
-
Richmond、Virginia、美国
-
Virginia Beach、Virginia、美国
-
-
Washington
-
Burien、Washington、美国
-
Edmonds、Washington、美国
-
Seattle、Washington、美国
-
Tacoma、Washington、美国
-
-
Wisconsin
-
Green Bay、Wisconsin、美国
-
Madison、Wisconsin、美国
-
Milwaukee、Wisconsin、美国
-
-
-
-
-
Helsinki、芬兰
-
Oulu、芬兰
-
Seinäjoki、芬兰
-
Tampere、芬兰
-
Turku、芬兰
-
-
-
-
-
Blackburn、英国
-
Cambridge、英国
-
Cardiff、英国
-
Dundee、英国
-
Glasgow、英国
-
Guildford、英国
-
Leeds、英国
-
London、英国
-
Maidstone、英国
-
Metropolitan Borough of Wirral、英国
-
Nottingham、英国
-
Plymouth、英国
-
Southampton、英国
-
Surrey、英国
-
Swansea、英国
-
Wolverhampton、英国
-
-
-
-
-
Alkmaar、荷兰
-
Eindhoven、荷兰
-
Hoofddorp、荷兰
-
Leidschendam、荷兰
-
Nijmegen、荷兰
-
Rotterdam、荷兰
-
-
-
-
-
A Coruña、西班牙
-
Badalona、西班牙
-
Barcelona、西班牙
-
Castellon、西班牙
-
Girona、西班牙
-
Guadalajara、西班牙
-
Jerez de la Frontera、西班牙
-
Las Palmas de Gran Canaria、西班牙
-
Madrid、西班牙
-
Murcia、西班牙
-
Málaga、西班牙
-
Palma de Mallorca、西班牙
-
Pamplona、西班牙
-
Sabadell、西班牙
-
Salamanca、西班牙
-
San Sebastián de los Reyes、西班牙
-
Santander、西班牙
-
Seville、西班牙
-
Valencia、西班牙
-
-
-
-
-
Daegu、韩国
-
Gwangju、韩国
-
Pusan、韩国
-
Seongnam、韩国
-
Seoul、韩国
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features with high risk for development of metastases, defined as prostate-specific antigen doubling time (PSADT) less than or equal to (<=) 10 months. PSADT is calculated using at least 3 prostate-specific antigen (PSA) values obtained during continuous ADT (androgen deprivation therapy)
- Castration-resistant prostate cancer demonstrated during continuous ADT, defined as 3 PSA rises, at least 1 week apart, with the last PSA greater than (>) 2 nanogram per milliliter (ng/mL)
- Maintain castrate levels of testosterone within 4 weeks prior to randomization and throughout the study
- Patients currently receiving bone loss prevention treatment with bone-sparing agents must be on stable doses for at least 4 weeks prior to randomization
- Patients who received a first generation anti-androgen (for example, bicalutamide, flutamide, nilutamide) must have at least a 4-week washout prior to randomization AND must show continuing disease (PSA) progression (an increase in PSA) after washout
- At least 4 weeks must have elapsed from the use of 5-alpha reductase inhibitors, estrogens, and any other anti-cancer therapy prior to randomization
- At least 4 weeks must have elapsed from major surgery or radiation therapy prior to randomization
- Eastern Cooperative Oncology Group Performance Status 0 or 1
- Resolution of all acute toxic effects of prior therapy or surgical procedure to Grade <= 1 or baseline prior to randomization
- Adequate organ function according to protocol-defined criteria
- Administration of growth factors or blood transfusions will not be allowed within 4 weeks of the hematology labs required to confirm eligibility
Exclusion Criteria:
- Presence of confirmed distant metastases, including central nervous system and vertebral or meningeal involvement
- Symptomatic local or regional disease requiring medical intervention
- Prior treatment with second generation anti-androgens
- Prior treatment with CYP17 inhibitors
- Prior treatment with radiopharmaceutical agents, or any other investigational agent for non-metastatic castration-resistant prostate cancer
- Prior chemotherapy for prostate cancer except if administered in the adjuvant/neoadjuvant setting
- History of seizure or condition that may pre-dispose to seizure
- Concurrent therapy with protocol-defined excluded medications
- History or evidence of any of the following conditions: any prior malignancy (other than adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, or any other cancer in situ currently in complete remission) within 5 years prior to randomization; severe/unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events, or clinically significant ventricular arrhythmias within 6 months prior to randomization; uncontrolled hypertension; gastrointestinal disorder affecting absorption; active infection; and, any other condition that, in the opinion of the investigator, would impair the patient's ability to comply with study procedures
学习计划
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：随机化
- 介入模型：并行分配
- 屏蔽：三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的：治疗组 A：阿帕他胺
|
240 mg tablets administered by mouth on a continuous once daily dosing regimen |
|
安慰剂比较：治疗组 B：安慰剂
|
Matched placebo tablets administered by mouth on a continuous once daily dosing regimen |
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Metastasis-Free Survival (MFS) by Blinded Independent Central Review (BICR)
大体时间：Up to approximately 43 Months
|
MFS was defined as the time from randomization to the time of first evidence of BICR-confirmed bone or soft tissue distant metastasis or death due to any cause, whichever occurred first. The MFS data for participants without metastasis or death were performed for US or ex-US regulatory purposes. Radiographic scans (bone scans and computerized tomography [CT] or magnetic resonance imaging [MRI] of the chest, abdomen, and pelvis) were performed for detection of metastasis throughout the study. |
Up to approximately 43 Months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Time to Metastasis (TTM)
大体时间：Up to approximately 43 Months
|
Time to metastasis (TTM) was defined as the time from randomization to the time of the scan that showed first evidence of BICR-confirmed radiographically detected bone or soft tissue distant metastasis. The TTM data for participants without metastasis were performed for US or ex-US regulatory purposes. Radiographic scans (bone scans and CT or MRI of the chest, abdomen, and pelvis) were performed for detection of metastasis throughout the study. |
Up to approximately 43 Months
|
|
Progression-free Survival (PFS)
大体时间：Up to approximately 43 Months
|
PFS defined as time from randomization to first documentation of BICR-confirmed radiographic progressive disease (PD) (development of distant/local/regional metastasis)/death due to any cause whichever occurred first. PFS data for participants without loco-regional disease were performed for US/ex-US regulatory purposes. Radiographic scans (bone scans and CT/MRI of chest,abdomen,pelvis) performed for detection of metastasis throughout study. PD based on RECIST v1.1; Subjects with one measurable lesion, At least 20% increase in sum of diameters of target lesions taking as reference smallest sum on study. In addition, sum must demonstrate an absolute increase of at least 5 millimeter(mm). Also, appearance of one/more new lesions was also considered PD. Subjects with non-measurable disease as per CT/MRI scans, unequivocal progression/appearance of one or more new lesions was considered PD. For new bone lesions detected on bone scans, second imaging (CT/MRI) was required to confirm PD. |
Up to approximately 43 Months
|
|
Time to Symptomatic Progression
大体时间：Up to approximately 43 Months
|
Time to symptomatic progression was defined as the time from randomization to documentation in the CRF of any of the following (whichever occurred earlier): a) development of a skeletal-related event (pathologic fracture, spinal cord compression, or need for surgical intervention or radiation therapy to the bone); b) pain progression or worsening of disease-related symptoms requiring initiation of a new systemic anti-cancer therapy; or c) development of clinically significant symptoms due to loco-regional tumor progression requiring surgical intervention or radiation therapy. |
Up to approximately 43 Months
|
|
Overall Survival
大体时间：Up to approximately 43 months
|
Overall survival was defined as the time from randomization to the date of death due to any cause. |
Up to approximately 43 months
|
|
Time to Initiation of Cytotoxic Chemotherapy
大体时间：Up to approximately 43 months
|
Time to initiation of cytotoxic chemotherapy was defined as the time from randomization to the date of initiation of cytotoxic chemotherapy for prostate cancer. |
Up to approximately 43 months
|
合作者和调查者
调查人员
- 研究主任：Aragon Pharmaceuticals, Inc. Clinical Trial、Aragon Pharmaceuticals, Inc.
出版物和有用的链接
一般刊物
- Chowdhury S, Oudard S, Uemura H, Joniau S, Dearden L, Capone C, Van Sanden S, Diels J, Hadaschik BA. Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison. Adv Ther. 2022 Jan;39(1):518-531. doi: 10.1007/s12325-021-01885-6. Epub 2021 Nov 19.
- Smith MR, Mehra M, Nair S, Lawson J, Small EJ. Relationship Between Metastasis-free Survival and Overall Survival in Patients With Nonmetastatic Castration-resistant Prostate Cancer. Clin Genitourin Cancer. 2020 Apr;18(2):e180-e189. doi: 10.1016/j.clgc.2019.10.030. Epub 2019 Nov 6.
- Saad F, Cella D, Basch E, Hadaschik BA, Mainwaring PN, Oudard S, Graff JN, McQuarrie K, Li S, Hudgens S, Lawson J, Lopez-Gitlitz A, Yu MK, Smith MR, Small EJ. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2018 Oct;19(10):1404-1416. doi: 10.1016/S1470-2045(18)30456-X. Epub 2018 Sep 10.
- Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ; SPARTAN Investigators. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. N Engl J Med. 2018 Apr 12;378(15):1408-1418. doi: 10.1056/NEJMoa1715546. Epub 2018 Feb 8.
- Pollock Y, Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik B, Olmos D, Lee JY, Uemura H, Bhaumik A, Londhe A, Rooney B, Brookman-May SD, De Porre P, Mundle SD, Small EJ. Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide. Prostate Cancer Prostatic Dis. 2023 Mar;26(1):156-161. doi: 10.1038/s41391-022-00592-9. Epub 2022 Oct 8.
- Uemura H, Koroki Y, Iwaki Y, Imanaka K, Kambara T, Lopez-Gitlitz A, Smith A, Uemura H. Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study. BMC Urol. 2020 Sep 2;20(1):139. doi: 10.1186/s12894-020-00689-0.
- Karsh LI, Bevans KB, Saad F, Chung BH, Oudard S, Brookman-May SD, McCarthy SA, Smith MR, Chi KN, Small EJ, Agarwal N. Prostate-specific antigen and health-related quality of life in individuals with advanced prostate cancer treated with apalutamide: a plain language summary of the SPARTAN and TITAN studies. Future Oncol. 2024;20(35):2689-2698. doi: 10.1080/14796694.2024.2384257. Epub 2024 Aug 20.
- Shen J, Chowdhury S, Agarwal N, Karsh LI, Oudard S, Gartrell BA, Feyerabend S, Saad F, Pieczonka CM, Chi KN, Brookman-May SD, Rooney B, Bhaumik A, McCarthy SA, Bevans KB, Mundle SD, Small EJ, Smith MR, Graff JN. Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN. Br J Cancer. 2024 Jan;130(1):73-81. doi: 10.1038/s41416-023-02492-8. Epub 2023 Nov 11.
- Ni X, Sui J, Wang B, Wang H, Freedland SJ, Ye D, Zhu Y. Lower Testosterone Level and Metastases-Free Survival in Patients With Nonmetastatic Castration-Resistant Prostate Cancer Treated With Novel Antiandrogens: A Post Hoc Analysis of SPARTAN and ARAMIS. J Urol. 2025 Jul;214(1):10-17. doi: 10.1097/JU.0000000000004545. Epub 2025 Mar 25.
- Feng FY, Smith MR, Saad F, Mobadersany P, Tian SK, Yip SSF, Greshock J, Khan N, Yu MK, McCarthy S, Brookman-May SD, Bourla AB, Todorovic T, Yamashita R, Huang HC, Royce TJ, Showalter TN, Griffin J, Mitani A, Esteva A, Small EJ. Digital Pathology-Based Multimodal Artificial Intelligence Scores and Outcomes in a Randomized Phase III Trial in Men With Nonmetastatic Castration-Resistant Prostate Cancer. JCO Precis Oncol. 2025 Jan;9:e2400653. doi: 10.1200/PO-24-00653. Epub 2025 Jan 31.
- Roy S, Malone S, Wing K, Chowdhury S, Kishan AU, Sun Y, Wallis CJD, Mohamad O, Jia AY, Swami U, Zaorsky NG, Morgan SC, Ong M, Agarwal N, Spratt DE, Small EJ, Saad F. Prior Local Therapy and First-Line Apalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of the SPARTAN Randomized Clinical Trial. JAMA Netw Open. 2024 Oct 1;7(10):e2439434. doi: 10.1001/jamanetworkopen.2024.39434.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- CR102931
- 2012-004322-24 (EudraCT编号)
- ARN-509-003; 56021927PCR1007 (其他标识符：Janssen Research & Development, LLC)
药物和器械信息、研究文件
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.